This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic (MDT) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 2.50% and 0.22%, respectively, for the quarter ended July 2024. Do the numbers hold clues to what lies ahead for the stock?
Cyclo Therapeutics, Inc. (CYTH) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cyclo Therapeutics (CYTH) delivered earnings and revenue surprises of -50% and 69.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
High Tide Inc. (HITI) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, High Tide Inc. (HITI) closed at $1.94, marking a -1.52% move from the previous day.
Brokers Suggest Investing in High Tide (HITI): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for High Tide (HITI) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
High Tide Inc. (HITI) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
High Tide Inc. (HITI) closed the most recent trading day at $1.71, moving -1.72% from the previous trading session.
High Tide Inc. (HITI) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
High Tide Inc. (HITI) reachead $1.83 at the closing of the latest trading day, reflecting a -1.61% change compared to its last close.
High Tide Inc. (HITI) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
High Tide Inc. (HITI) concluded the recent trading session at $1.86, signifying a -1.59% move from its prior day's close.
Wall Street Bulls Look Optimistic About High Tide (HITI): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in High Tide (HITI). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Here is What to Know Beyond Why High Tide Inc. (HITI) is a Trending Stock
by Zacks Equity Research
High Tide (HITI) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
High Tide Inc. (HITI) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
High Tide Inc. (HITI) closed the most recent trading day at $1.94, moving +1.04% from the previous trading session.
Will Clear Aligner Sales Drive Align Technology's (ALGN) Q2 Earnings?
by Zacks Equity Research
Align Technology's (ALGN) second-quarter results are likely to reflect the strength in its Clear Aligner and Systems & Services businesses.
Is aTyr Pharma (ATYR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Atyr Pharma (ATYR) and High Tide Inc. (HITI) have performed compared to their sector so far this year.
High Tide Inc. (HITI) Reports Break-Even Earnings for Q2
by Zacks Equity Research
High Tide (HITI) delivered earnings and revenue surprises of 100% and 2.73%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think High Tide (HITI) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for High Tide (HITI) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
High Tide Inc. (HITI) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
High Tide Inc. (HITI) reachead $2.54 at the closing of the latest trading day, reflecting a +0.4% change compared to its last close.
HealthEquity (HQY) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 21.21% and 3.16%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Canopy Growth (CGC) delivered earnings and revenue surprises of 15.15% and 2.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
High Tide Inc. (HITI) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
High Tide Inc. (HITI) reachead $2.38 at the closing of the latest trading day, reflecting no change compared to its last close.
High Tide (HITI) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), High Tide (HITI) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
by Zacks Equity Research
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.
Here's Why You Should Hold on to Abbott (ABT) Stock for Now
by Zacks Equity Research
Abbott's (ABT) share recovery in the Nutrition business buoys optimism.
High Tide Inc. (HITI) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
High Tide Inc. (HITI) closed at $2.18 in the latest trading session, marking a -1.36% move from the prior day.
IDEXX (IDXX) Witnesses Rising Expenses, Currency Issues
by Zacks Equity Research
IDEXX (IDXX) is being hurt by geopolitical instability, including the current war in Ukraine, which has affected supply chain operations globally.
Here's Why Investors Should Buy ResMed (RMD) Stock Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) potential in digital health and expansion in the international market.
Medtronic (MDT) Reports Favorable SPHERE Per-AF Trial Outcome
by Zacks Equity Research
Medtronic's (MDT) Affera Mapping and Ablation System with Sphere-9 Catheter achieves endpoints for safety and efficacy for the treatment of AFib.